Please login to the form below

Not currently logged in

Horizon appoints board chair

Dr Ian Gilham assumes position full-time
Horizon Ian Gilham

Horizon Discovery has appointed Dr Ian Gilham as chairman of its board of directors on a permanent basis after he spent several months as its interim chairman.

The UK-based genetic research firm will look to benefit from Dr Gilham's thirty years of industry experience, which includes his role as CEO of in vitro diagnostics company Axis-Shield.

He held this role until from 2008 to 2011, when the company was acquired by Alere.

Dr Gilham's prior experience also includes senior positions at leading pharma companies, such as GlaxoSmithKline and Abbott Labs.

Horizon's CEO Dr Darrin Disley said: “As interim chairman [Dr Gilham] has made an invaluable contribution to the growth and success of the Company and we look forward to benefitting from his guidance as Horizon continues to develop as a world-leading translational genomics organisation."

These growth prospects include a partnership with AstraZeneca to research personalised treatments in oncology.

17th January 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...